ACT Capital Partners, L.P.’s Crescent Biopharma CBIO Stock Holding History

ACT Capital Partners, L.P.’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$168K	Buy	+11,500	New	+$193K	0.11%	51

Other funds holding CBIO

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

ACT Capital Partners, L.P.'s CBIO Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Crescent Biopharma (CBIO) in Q3 2026: 11,500 shares worth $168K. The stake represents 0.11% of the portfolio and ranks #51 among its holdings.

23 funds tracked by Wall St. Rank hold CBIO as of Q3 2026.

ACT Capital Partners, L.P. held 11,500 shares of Crescent Biopharma worth $168K as of Q3 2026.
Crescent Biopharma was a new ACT Capital Partners, L.P. position in Q3 2026.
Crescent Biopharma made up 0.11% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #51 holding.
23 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.